Explicyte is the first immuno-oncology CRO in Europe equipped with the 10x Xenium platform for single-cell spatial transcriptomics! Training by the 10x Genomics team started! Why is it exciting for immuno-oncology?
“For our translational and data science team, the Xenium platform opens unexplored avenues for analyzing tumors and their microenvironment in response to various cancer modalities, including immunotherapies.
For our sponsors, gaining a deep understanding of the gene expression profiles and spatial distribution of individual cells within a tumor specimen can provide unique insights into understanding tumor biology, and mechanisms at play in anti-cancer response or resistance to treatment. It creates opportunities to identify new targets and biomarkers to predict clinical outcomes for cancer patients.
As a researcher, I’m eager to watch tumor cells, immune cells, cancer-associated fibroblasts with the Xenium eye, and to witness the single-cell architecture of immune infiltrates and tertiary lymphoid structures. We are truly excited as we enter a new era of cancer discovery.”
Alban Bessede, CEO of Explicyte Immuno-Oncology.
About the 10x Xenium platform:
- Compatible with standard tumor specimens (frozen & FFPE)
- TME architecture is visualized at subcellular level with a 5000-gene panel
- Single-cell analysis & segmentation with AI-driven algorithm
Learn about our services for target identification & biomarker discovery in immuno-oncology.